To evaluate and compare the risks of secondary cancers from therapeutic doses received by patients with hepatocellular carcinoma ( HCC ) during intensity-modulated radiotherapy ( IMRT ) , volumetric arc therapy ( VMAT ) , and tomotherapy ( TOMO ) .